Details for Patent: 10,842,801
✉ Email this page to a colleague
Which drugs does patent 10,842,801 protect, and when does it expire?
Patent 10,842,801 protects KORLYM and is included in one NDA.
Summary for Patent: 10,842,801
Title: | Optimizing mifepristone absorption |
Abstract: | The present invention provides a method for altering the pharmacokinetics of mifepristone upon oral administration. Mifepristone absorption into the blood is increased upon administration with meals. The method of the invention can benefit patients suffering from conditions including psychiatric illnesses and hormonal disorders. |
Inventor(s): | Belanoff; Joe (Menlo Park, CA), Roe; Robert (Menlo Park, CA), Loewy; Caroline (Menlo Park, CA) |
Assignee: | Corcept Therapeutics, Inc. (Menlo Park, CA) |
Application Number: | 16/574,780 |
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 10,842,801
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Corcept Therap | KORLYM | mifepristone | TABLET;ORAL | 202107-001 | Feb 17, 2012 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | TREATING CUSHING'S SYNDROME | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |